262 related articles for article (PubMed ID: 11172346)
1. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
Perry CM; Jarvis B
BioDrugs; 2002; 16(3):213-7. PubMed ID: 12102649
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon monotherapy for chronic hepatitis C.
Heathcote J; Zeuzem S
Semin Liver Dis; 2004; 24 Suppl 2():39-45. PubMed ID: 15346245
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.
Perry CM; Jarvis B
Drugs; 2001; 61(15):2263-88. PubMed ID: 11772139
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS).
Bressler B; Wang K; Grippo JF; Heathcote EJ
Br J Clin Pharmacol; 2009 Mar; 67(3):280-7. PubMed ID: 19523011
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study.
Sulkowski M; Reindollar R; Thomas DL; Brinkley-Laughton S; Hudson M; Yu J
BioDrugs; 2002; 16(2):105-9. PubMed ID: 11985484
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alfa-2a in patients with chronic hepatitis C.
Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
[TBL] [Abstract][Full Text] [Related]
9. Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection.
Lurie Y; Rouzier-Panis R; Webster GJ; Dusheiko GM; Laughlin M; Jackson ML; Oren R
Clin Gastroenterol Hepatol; 2005 Jun; 3(6):610-5. PubMed ID: 15952104
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferons for the treatment of chronic hepatitis C infection.
Luxon BA; Grace M; Brassard D; Bordens R
Clin Ther; 2002 Sep; 24(9):1363-83. PubMed ID: 12380630
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
[TBL] [Abstract][Full Text] [Related]
12. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
Covic A; Maftei ID; Mardare NG; Ioniţă-Radu F; Totolici C; Tuţă L; Golea O; Covic M; Volovăţ C; Gusbeth-Tatomir P; Mircescu G
J Nephrol; 2006; 19(6):794-801. PubMed ID: 17173254
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.
Chan TM; Ho SK; Tang CS; Tse KC; Lam MF; Lai KN; Yung S
Nephrology (Carlton); 2007 Feb; 12(1):11-7. PubMed ID: 17295655
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.
Pockros PJ; Carithers R; Desmond P; Dhumeaux D; Fried MW; Marcellin P; Shiffman ML; Minuk G; Reddy KR; Reindollar RW; Lin A; Brunda MJ;
Am J Gastroenterol; 2004 Jul; 99(7):1298-305. PubMed ID: 15233669
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy, influencing factors and safety of PEG-INF alpha-2a (PEG-INF-2a) in the treatment of chronic hepatitis C: analysis of 89 patients].
Ma LN; Chen XY; Chen J; Shen CL; Wang JT
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):42-5. PubMed ID: 16816861
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
Rasenack J; Zeuzem S; Feinman SV; Heathcote EJ; Manns M; Yoshida EM; Swain MG; Gane E; Diago M; Revicki DA; Lin A; Wintfeld N; Green J
Pharmacoeconomics; 2003; 21(5):341-9. PubMed ID: 12627987
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C.
Sebastiani G; Ferrari A; Boccato S; Pistis R; Alberti A
Aliment Pharmacol Ther; 2007 Oct; 26(7):1077-82. PubMed ID: 17877515
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.
Tanwar S; Wright M; Foster GR; Ryder SD; Mills PR; Cramp ME; Parkes J; Rosenberg WM
Eur J Gastroenterol Hepatol; 2012 May; 24(5):543-50. PubMed ID: 22337287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
